Asthma Treatment Market

Asthma Treatment Market Study by Inhaled, Oral, Intravenous, and Subcutaneous for Long-term Asthma Control Medications and and Quick-relief (Rescue) Medications from 2023 to 2033

Analysis of Asthma Treatment Market Covering 30+ Countries Including Analysis of US, Canada, UK, Germany, France, Nordics, GCC countries, Japan, Korea and many more

Table of Content

1. Preface

    1.1. Market Definition and Scope

    1.2. Market Segmentation

    1.3. Key Research Objectives

    1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Market

4. Market Overview

    4.1. Introduction

    4.2. Overview

    4.3. Market Dynamics

        4.3.1. Drivers

        4.3.2. Restraints

        4.3.3. Opportunities

4.4. Global Market Analysis and Forecast, 2023–2027

5. Market Outlook

    5.1. Pipeline Analysis

    5.2. Reimbursement Scenario

    5.3. Disease Prevalence with Key Countries

6. Global Market Analysis and Forecasts, by Treatment Type

    6.1. Introduction & Definition

    6.2. Key Findings / Developments

    6.3. Global Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2027

        6.3.1. Long-term Asthma Control Medications

            6.3.1.1. Inhaled Corticosteroids

            6.3.1.2. Leukotriene Modifiers

            6.3.1.3. Long-acting Beta Agonists

            6.3.1.4. Combination Inhalers

            6.3.1.5. Theophylline

            6.3.1.6. Others (reslizumab, benralizumab, etc.)

        6.3.2. Quick-relief (rescue) Medications

            6.3.2.1. Short-acting Beta Agonists

            6.3.2.2. Ipratropium (Atrovent)

            6.3.2.3. Oral and Intravenous Corticosteroids

    6.4. Global Market Attractiveness, by Treatment Type

7. Global Market Analysis and Forecasts, by Route of Administration

    7.1. Introduction & Definition

    7.2. Key Findings / Developments

    7.3. Global Market Value (US$) Forecast, by Route of Administration, 2023–2027

        7.3.1. Oral

        7.3.2. Inhaled

        7.3.3. Intravenous

        7.3.4. Subcutaneous

    7.4. Global Market Attractiveness, by Route of Administration

8. Global Market Analysis and Forecasts, by Distribution Channel

    8.1. Introduction & Definition

    8.2. Key Findings / Developments

    8.3. Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2027

        8.3.1. Hospital Pharmacies

        8.3.2. Retail Pharmacies

        8.3.3. Online Pharmacies

    8.4. Global Market Attractiveness, by Distribution Channel

9. Global Market Analysis and Forecasts, by Region

    9.1. Key Findings

    9.2. Global Market Value (US$ Mn) Forecast, by Region

        9.2.1. North America

        9.2.2. Europe

        9.2.3. Asia Pacific

        9.2.4. Latin America

        9.2.5. Middle East & Africa

    9.3. Global Market Attractiveness, by Region

10. North America Market Analysis and Forecast

    10.1. Introduction

    10.2. North America Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2027

        10.2.1. Long-term Asthma Control Medications

            10.2.1.1. Inhaled Corticosteroids

            10.2.1.2. Leukotriene Modifiers

            10.2.1.3. Long-acting Beta Agonists

            10.2.1.4. Combination Inhalers

            10.2.1.5. Theophylline

            10.2.1.6. Others (reslizumab, benralizumab, etc.)

        10.2.2. Quick-relief (rescue) Medications

            10.2.2.1. Short-acting Beta Agonists

            10.2.2.2. Ipratropium (Atrovent)

            10.2.2.3. Oral and Intravenous Corticosteroids

    10.3. North America Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2027

        10.3.1. Oral

        10.3.2. Inhaled

        10.3.3. Intravenous

        10.3.4. Subcutaneous

    10.4. North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2027

        10.4.1. Hospital Pharmacies

        10.4.2. Retail Pharmacies

        10.4.3. Online Pharmacies

    10.5. North America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2027

        10.5.1. U.S.

        10.5.2. Canada

    10.6. North America Market Attractiveness Analysis

        10.6.1. By Treatment Type

        10.6.2. By Route of Administration

        10.6.3. By Distribution Channel

        10.6.4. By Country/Sub-region

11. Europe Market Analysis and Forecast

    11.1. Introduction

    11.2. Europe Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2027

        11.2.1. Long-term Asthma Control Medications

            11.2.1.1. Inhaled Corticosteroids

            11.2.1.2. Leukotriene Modifiers

            11.2.1.3. Long-acting Beta Agonists

            11.2.1.4. Combination Inhalers

            11.2.1.5. Theophylline

            11.2.1.6. Others (reslizumab, benralizumab etc.)

        11.2.2. Quick-relief (rescue) Medications

            11.2.2.1. Short-acting Beta Agonists

            11.2.2.2. Ipratropium (Atrovent)

            11.2.2.3. Oral and Intravenous Corticosteroids

    11.3. Europe Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2027

        11.3.1. Oral

        11.3.2. Inhaled

        11.3.3. Intravenous

        11.3.4. Subcutaneous

    11.4. Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2027

        11.4.1. Hospital Pharmacies

        11.4.2. Retail Pharmacies

        11.4.3. Online Pharmacies

    11.5. Europe Market Value (US$ Mn) Forecast, by Country/Sub-region , 2023–2027

        11.5.1. Germany

        11.5.2. U.K.

        11.5.3. France

        11.5.4. Spain

        11.5.5. Italy

        11.5.6. Rest of Europe

    11.6. Europe Market Attractiveness Analysis

        11.6.1. By Treatment Type

        11.6.2. By Route of Administration

        11.6.3. By Distribution Channel

        11.6.4. By Country/Sub-region

12. Asia Pacific Market Analysis and Forecast

    12.1. Introduction

    12.2. Asia Pacific Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2027

        12.2.1. Long-term Asthma Control Medications

            12.2.1.1. Inhaled Corticosteroids

            12.2.1.2. Leukotriene Modifiers

            12.2.1.3. Long-acting Beta Agonists

            12.2.1.4. Combination Inhalers

            12.2.1.5. Theophylline

            12.2.1.6. Others (reslizumab, benralizumab etc.)

        12.2.2. Quick-relief (rescue) Medications

            12.2.2.1. Short-acting Beta Agonists

            12.2.2.2. Ipratropium (Atrovent)

            12.2.2.3. Oral and Intravenous Corticosteroids

    12.3. Asia Pacific Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2027

        12.3.1. Oral

        12.3.2. Inhaled

        12.3.3. Intravenous

        12.3.4. Subcutaneous

    12.4. Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2027

        12.4.1. Hospital Pharmacies

        12.4.2. Retail Pharmacies

        12.4.3. Online Pharmacies

    12.5. Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region , 2023–2027

        12.5.1. China

        12.5.2. Japan

        12.5.3. India

        12.5.4. Australia & New Zealand

        12.5.5. Rest of Asia Pacific

    12.6. Asia Pacific Market Attractiveness Analysis

        12.6.1. By Treatment Type

        12.6.2. By Route of Administration

        12.6.3. By Distribution Channel

        12.6.4. By Country/Sub-region

13. Latin America Market Analysis and Forecast

    13.1. Introduction

    13.2. Latin America Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2027

        13.2.1. Long-term Asthma Control Medications

            13.2.1.1. Inhaled Corticosteroids

            13.2.1.2. Leukotriene Modifiers

            13.2.1.3. Long-acting Beta Agonists

            13.2.1.4. Combination Inhalers

            13.2.1.5. Theophylline

            13.2.1.6. Others (reslizumab, benralizumab etc.)

        13.2.2. Quick-relief (rescue) Medications

            13.2.2.1. Short-acting Beta Agonists

            13.2.2.2. Ipratropium (Atrovent)

            13.2.2.3. Oral and Intravenous Corticosteroids

    13.3. Latin America Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2027

        13.3.1. Oral

        13.3.2. Inhaled

        13.3.3. Intravenous

        13.3.4. Subcutaneous

    13.4. Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2027

        13.4.1. Hospital Pharmacies

        13.4.2. Retail Pharmacies

        13.4.3. Online Pharmacies

    13.5. Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region , 2023–2027

        13.5.1. Brazil

        13.5.2. Mexico

        13.5.3. Rest of Latin America

    13.6. Latin America Market Attractiveness Analysis

        13.6.1. By Treatment Type

        13.6.2. By Route of Administration

        13.6.3. By Distribution Channel

        13.6.4. By Country/Sub-region

14. Middle East & Africa Market Analysis and Forecast

    14.1. Introduction

    14.2. Middle East & Africa Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2027

        14.2.1. Long-term Asthma Control Medications

            14.2.1.1. Inhaled Corticosteroids

            14.2.1.2. Leukotriene Modifiers

            14.2.1.3. Long-acting Beta Agonists

            14.2.1.4. Combination Inhalers

            14.2.1.5. Theophylline

            14.2.1.6. Others (reslizumab, benralizumab etc.)

        14.2.2. Quick-relief (rescue) Medications

            14.2.2.1. Short-acting Beta Agonists

            14.2.2.2. Ipratropium (Atrovent)

            14.2.2.3. Oral and Intravenous Corticosteroids

    14.3. Middle East & Africa Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2027

        14.3.1. Oral

        14.3.2. Inhaled

        14.3.3. Intravenous

        14.3.4. Subcutaneous

    14.4. Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2027

        14.4.1. Hospital Pharmacies

        14.4.2. Retail Pharmacies

        14.4.3. Online Pharmacies

    14.5. Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region , 2023–2027

        14.5.1. GCC

        14.5.2. South Africa

        14.5.3. Rest of Middle East & Africa

    14.6. Middle East & Africa Market Attractiveness Analysis

        14.6.1. By Treatment Type

        14.6.2. By Route of Administration

        14.6.3. By Distribution Channel

        14.6.4. By Country/Sub-region

15. Competition Landscape

    15.1. Market Share Analysis, by Company (2022)

    15.2. Company Profiles

        15.2.1. AstraZeneca

        15.2.2. Boehringer Ingelheim International GmbH

        15.2.3. GlaxoSmithKline plc

        15.2.4. Novartis AG

        15.2.5. Teva Pharmaceutical Industries Ltd

        15.2.6. Sumitomo Dainippon Pharma Co., Ltd

        15.2.7. Merck & Co., Inc.

        15.2.8. F. Hoffmann-La Roche Ltd.

        15.2.9. Sanofi

        15.2.10. Mylan N.V.

Don't Need a Global Report?

save 40%! on Country & Region specific reports

List Of Table

Table 01: Pipeline Analysis

Table 02: Pipeline Analysis

Table 03: Pipeline Analysis

Table 04: Global Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2033

Table 05: Global Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023–2033

Table 06: Global Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023–2033

Table 07: Global Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033

Table 08: Global Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 09: Global Market Value (US$ Mn) Forecast, by Region, 2023–2033

Table 10: North America Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2033

Table 11: North America Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023–2033

Table 12: North America Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023–2033

Table 13: North America Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033

Table 14: North America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 15: North America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 16: Europe Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2033

Table 17: Europe Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023–2033

Table 18: Europe Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023–2033

Table 19: Europe Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033

Table 20: Europe Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 21: Europe Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 22: Asia Pacific Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2033

Table 23: Asia Pacific Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023–2033

Table 24: Asia Pacific Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023–2033

Table 25: Asia Pacific Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033

Table 26: Asia Pacific Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 27: Asia Pacific Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 28: Latin America Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2033

Table 29: Latin America Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023–2033

Table 30: Latin America Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023–2033

Table 31: Latin America Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033

Table 32: Latin America Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 33: Latin America Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

Table 34: Middle East & Africa Market Value (US$ Mn) Forecast, by Treatment Type, 2023–2033

Table 35: Middle East & Africa Market Value (US$ Mn) Forecast, by Long-term Asthma Control Medications, 2023–2033

Table 36: Middle East & Africa Market Value (US$ Mn) Forecast, by Quick-relief (rescue) Medications, 2023–2033

Table 37: Middle East & Africa Market Value (US$ Mn) Forecast, by Route of Administration, 2023–2033

Table 38: Middle East & Africa Market Value (US$ Mn) Forecast, by Distribution Channel, 2023–2033

Table 39: Middle East & Africa Market Value (US$ Mn) Forecast, by Country/Sub-region, 2023–2033

More Insights, Lesser Cost (-50% off)

Insights on import/export production,
pricing analysis, and more – Only @ Fact.MR

List Of Figures

Figure 01: Global Market Value (US$ Mn) and Distribution Channel, by Region, 2022 and 2033

Figure 02: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033

Figure 03: Global Market Value Share Analysis, by Treatment Type, 2022 and 2033

Figure 04: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Long-term Asthma Control Medications, 2023–2033

Figure 05: Global Market Value (US$ Mn) and Y-o-Y Growth (%), by Quick-relief (rescue) Medications, 2023–2033

Figure 06: Global Market Attractiveness Analysis, by Treatment Type, 2022–2033

Figure 07: Global Market Value Share Analysis, by Route of Administration, 2022 and 2033

Figure 08: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Inhaled, 2023–2033

Figure 09: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Oral, 2023–2033

Figure 10: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Intravenous, 2023–2033

Figure 11: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Subcutaneous, 2023–2033

Figure 12: Global Market Attractiveness Analysis, by Route of Administration, 2022–2033

Figure 13: Global Market Value Share Analysis, by Distribution Channel, 2022 and 2033

Figure 14: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Retail Pharmacies, 2023–2033

Figure 15: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Hospital Pharmacies, 2023–2033

Figure 16: Global Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, by Online Pharmacies, 2023–2033

Figure 17: Global Market Attractiveness Analysis, by Distribution Channel, 2022–2033

Figure 18: Global Market Value Share Analysis, by Region, 2022 and 2033

Figure 19: Global Market Attractiveness Analysis, by Region, 2022–2033

Figure 20: North America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033

Figure 21: North America Market Value Share Analysis, by Treatment Type, 2022 and 2033

Figure 22: North America Market Attractiveness Analysis, by Treatment Type, 2022–2033

Figure 23: North America Market Value Share Analysis, by Route of Administration, 2022 and 2033

Figure 24: North America Market Attractiveness Analysis, by Route of Administration, 2022–2033

Figure 25: North America Market Value Share Analysis, by Distribution Channel, 2022 and 2033

Figure 26: North America Market Attractiveness Analysis, by Distribution Channel, 2022–2033

Figure 27: North America Market Value Share Analysis, by Country, 2022 and 2033

Figure 28: North America Market Attractiveness Analysis, by Country, 2022–2033

Figure 29: Europe Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033

Figure 30: Europe Market Value Share Analysis, by Treatment Type, 2022 and 2033

Figure 31: Europe Market Attractiveness Analysis, by Treatment Type, 2022–2033

Figure 32: Europe Market Value Share Analysis, by Route of Administration, 2022 and 2033

Figure 33: Europe Market Attractiveness Analysis, by Route of Administration, 2022–2033

Figure 34: Europe Market Value Share Analysis, by Distribution Channel, 2022 and 2033

Figure 35: Europe Market Attractiveness Analysis, by Distribution Channel, 2022–2033

Figure 36: Europe Market Value Share Analysis, by Country/Sub-Region, 2022 and 2033

Figure 37: Europe Market Attractiveness Analysis, by Country/Sub-region, 2022–2033

Figure 38: Asia Pacific Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033

Figure 39: Asia Pacific Market Value Share Analysis, by Treatment Type, 2022 and 2033

Figure 40: Asia Pacific Market Attractiveness Analysis, by Treatment Type, 2023–2033

Figure 41: Asia Pacific Market Value Share Analysis, by Route of Administration, 2022 and 2033

Figure 42: Asia Pacific Market Attractiveness Analysis, by Route of Administration, 2022–2033

Figure 43: Asia Pacific Market Value Share Analysis, by Distribution Channel, 2022 and 2033

Figure 44: Asia Pacific Market Attractiveness Analysis, by Distribution Channel, 2022 - 2033

Figure 45: Asia Pacific Market Value Share Analysis, by Country/Sub-region, 2022 and 2033

Figure 46: Asia Pacific Market Attractiveness Analysis, by Country/Sub-region, 2022–2033

Figure 47: Latin America Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033

Figure 48: Latin America Market Value Share Analysis, by Treatment Type, 2022 and 2033

Figure 49: Latin America Market Attractiveness Analysis, by Treatment Type, 2022–2033

Figure 50: Latin America Market Value Share Analysis, by Route of Administration, 2022 and 2033

Figure 51: North America Market Attractiveness Analysis, by Route of Administration, 2022–2033

Figure 52: Latin America Market Value Share Analysis, by Distribution Channel, 2022 and 2033

Figure 53: Latin America Market Attractiveness Analysis, by Distribution Channel, 2022–2033

Figure 54: Latin America Market Value Share Analysis, by Country/Sub-region, 2022 and 2033

Figure 55: Latin America Market Attractiveness Analysis, by Country/Sub-region, 2022–2033

Figure 56: Middle East & Africa Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2023–2033

Figure 57: Middle East & Africa Market Value Share Analysis, by Treatment Type, 2022 and 2033

Figure 58: Middle East & Africa Market Attractiveness Analysis, by Treatment Type, 2022–2033

Figure 59: Middle East & Africa Market Value Share Analysis, by Route of Administration, 2022 and 2033

Figure 60: Middle East & Africa Market Attractiveness Analysis, by Route of Administration, 2022–2033

Figure 61: Middle East & Africa Market Value Share Analysis, by Distribution Channel, 2022 and 2033

Figure 62: Middle East & Africa Market Attractiveness Analysis, by Distribution Channel, 2022?2033

Figure 63: Middle East & Africa Market Value Share Analysis, by Country/Sub-region, 2022 and 2033

Figure 64: Middle East & Africa Market Attractiveness Analysis, by Country/Sub-region, 2022–2033

Figure 65: Global Market Share, by Company, 2022

Figure 66: AstraZeneca Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2022

Figure 67: AstraZeneca Respiratory Segment Revenue (US$ Mn) and Y-o-Y Growth (%), 2018-2022

Figure 68: AstraZeneca Breakdown of Net Sales (%), by Product Segment, 2022

Figure 69: Boehringer Ingelheim International GmbH Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 70: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Region, 2022

Figure 71: Boehringer Ingelheim International GmbH R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 72: Boehringer Ingelheim International GmbH Breakdown of Net Sales (%), by Business Segment, 2022

Figure 73: GlaxoSmithKline plc Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 74: GlaxoSmithKline plc Breakdown of Net Sales (%), by Region, 2022

Figure 75: GlaxoSmithKline plc R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 76: GlaxoSmithKline plc Breakdown of Net Sales (%), by Business Segment, 2022

Figure 77: Novartis AG Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 78: Novartis AG Breakdown of Net Sales (%), by Country, 2022

Figure 79: Novartis AG R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 80: Novartis AG Breakdown of Net Sales (%), by Business Segment, 2022

Figure 81: Teva Pharmaceutical Industries Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 82: Teva Pharmaceutical Industries Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 83: Teva Pharmaceutical Industries Ltd Breakdown of Net Sales (%), by Segment, 2022

Figure 84: Sumitomo Dainippon Pharma Co., Ltd Revenue (US$ Mn) and Y-o-Y Growth (%), 2014–2022

Figure 85: Sumitomo Dainippon Pharma Co., Ltd Breakdown of Pharmaceutical Net Sales (%), by Region, 2017

Figure 86: Sumitomo Dainippon Pharma Co., Ltd R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2014–2022

Figure 87: Breakdown of Sumitomo Dainippon Pharma Co., Ltd Net Sales (%), by Product Segment, 2017

Figure 88: Merck & Co., Inc. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 89: Merck & Co., Inc. Breakdown of Net Sales (%), by Region, 2022

Figure 90: Merck & Co., Inc. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 91: Merck & Co., Inc. Breakdown of Net Sales (%), by Business Segment, 2022

Figure 92: F. Hoffmann-La Roche Ltd. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 93: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales (%), by Region, 2022

Figure 94: F. Hoffmann-La Roche Ltd. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 95: F. Hoffmann-La Roche Ltd. Breakdown of Net Sales (%), by Business Segment, 2022

Figure 96: Sanofi Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 97: Sanofi Breakdown of Net Sales (%), by Region, 2022

Figure 98: Sanofi Revenue Breakdown of Net Sales (%), by Business segment, 2022

Figure 99: Sanofi R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 100: Mylan N.V. Revenue (US$ Mn) and Y-o-Y Growth (%), 2018–2022

Figure 101: Mylan N.V. R&D Expenses (US$ Mn) and Y-o-Y Growth (%), 2018-2022

Figure 102: Mylan N.V. Breakdown of Net Sales (%), by Region, 2022

Know thy Competitors

Competitive landscape highlights only certain players
Complete list available upon request

Asthma Treatment Market

Schedule a Call